Fig. 6

OT-9 increases sarcospan mRNA in vitro and in vivo in mdx muscle. a Schematic overview of experimental setup to test sarcospan mRNA stability in vitro. C2C12 myotubes were treated on the second day of differentiation with 5 μM of OT-9. After 4 h, the medium containing OT-9 was removed and changed to fresh medium without compound. The cells were harvested for gene expression analysis immediately after medium change (0 h), and 4 h, 24 h, and 48 h after. b OT-9 induced sarcospan gene expression after 4 h of treatment (0 h). After extended removal of the compound (4–48 h), sarcospan mRNA levels were the same in cells treated with vehicle and OT-9. c 20-week-old male mdx littermates were injected in both tibialis anterior muscles with vehicle (5% DMSO, 95% PBS) or 3 mg/kg  of OT-9. After 4 h, the muscles were harvested and processed for gene expression analysis. Gene expression was normalized to β-actin and vehicle-treated cells. Data represents individual replicates and mean value. n = 3 for in vitro and n = 2 for in vivo study. SSPN, sarcospan; R.U., relative units. **p < 0.01, ****p < 0.0001